To prevent confounding from cell types with potential high STIM1 score, we further restricted the bulk sample with tumor purity of > 80% (based on immunohistochemistry (IHC)), resulting in 277 (of 471, 58.8%) patients. This evidence concerns the gene STIM1 and neoplasm.